Skip to main content

Table 1 Characteristics of the Fabry mutations tested by expression in COS-7 cells

From: Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests

Mutant: nucleotide

Amino acid

fold increase

PSSM

MUPRO

SDM

PSAmc

PSAsc

sec_stru

domain

Active site

Pheno type

ref

c.688G > A

p.A230T

2.1

0

-2.33

-0.48

4

64.8

P(5)

TIM

Yes

Classic

[24]

c.730G > C

p.D244H

3.3

-1

-1.74

0.379

18.6

48.7

A(11)

TIM

No

Classic

[31]

c.805G > A

p.V269M

2.5

0

-0.77

-0.212

3.2

0

O(12)

TIM

No

Classic

[28]

c.838C > A

p.Q280K

3.1

0

-1.00

-1.126

0

17.3

A(14)

TIM

No

Classic

[32]

c.898C > T

p.L300F

5.8

-1

-1.60

-0.732

9.9

0

O(6)

TIM

No

?

[30]

c.902G > C

p.R301P

3.7

-1

-1.68

-1.228

65.2

17.5

O(6)

TIM

No

Classic

[25]

c.928C > T

p.L310F

8.9

0

-1.34

-1.334

1.7

5.1

A(5)

TIM

No

Classic

[26]

c.1023A > C

p.E341D

2.2

-1

-0.88

-1.055

0

0

B(9)

beta

No

Classic

[27]

c.1228A > G

p.T410A

3.5

-1

-1.47

0.215

0

0

O(1)

beta

No

Variant

[29]

  1. Mutations tested by transient transfection are listed together with their responsiveness to 1-deoxy-galactonojirimycin expressed as fold increase, the scores obtained by PSSM (assessment of conservation in homologous sequences), the scores obtained by SDM and MUPRO (assessment of the effect of mutations on thermodynamic stability), % main chain accessibility (PSAmc), % side chain accessibility (PSAsc), occurrence in A alpha-helix, B beta strand, P poly-proline II or O other (with the length of the secondary structure in which the mutation occur in brackets), occurrence in specific structural domains and in the active site. Severity in patients was deduced from literature and the reference paper is reported alongside.